Kazia Therapeutics (KZIA) Total Current Liabilities (2009 - 2025)

Kazia Therapeutics has reported Total Current Liabilities for 15 years, with the latest figure at $16.0 million in Q4 2025.

• For the quarter ending Q4 2025, Total Current Liabilities rose 48.2% year-over-year to $16.0 million; the trailing twelve-month figure through Dec 2025 stood at $16.0 million (up 48.2% YoY), and the FY2025 full-year result was $9.0 million, down 47.06% from the prior year.
• Total Current Liabilities for Q4 2025 stood at $16.0 million, up from $9.0 million in the prior quarter.
• The five-year high for Total Current Liabilities was $17.0 million in Q2 2024, with the low at $3.7 million in Q4 2022.
• Historically, Total Current Liabilities has averaged $8.6 million across 5 years, with a median of $6.9 million in 2021.
• Annual changes were most pronounced in 2024 — Total Current Liabilities jumped 236.24% — and 2025, when it slumped 47.06%.
• Kazia Therapeutics' Total Current Liabilities stood at $5.5 million in 2021, then sank by 33.7% to $3.7 million in 2022, then surged by 101.2% to $7.4 million in 2023, then jumped by 46.33% to $10.8 million in 2024, then soared by 48.2% to $16.0 million in 2025.
• The last three Total Current Liabilities figures came in at $16.0 million (Q4 2025), $9.0 million (Q2 2025), and $10.8 million (Q4 2024), per Business Quant data.